US biotechnology company Scholar Rock is approaching a pivotal moment as it awaits a decision from the US Food and Drug Administration (FDA) on its experimental drug apitegromab, a treatment for spinal muscular atrophy (SMA). The company has also submitted the drug for review by the European Medicines Agency (EMA), with a potential EU approval that could eventually benefit patients in the United Kingdom.
Shares in Scholar Rock have climbed in recent weeks as investor sentiment has been buoyed by positive clinical trial data. The drug, a muscle-targeted therapy, has shown promise in improving motor function in patients with SMA, a rare genetic condition that causes progressive muscle weakness. Analysts have noted that apitegromab could address an unmet need for patients who do not respond adequately to existing treatments.
For UK patients and the National Health Service, the path to availability depends on a chain of regulatory steps. Even if the EMA grants approval, the drug would still require a separate assessment by the National Institute for Health and Care Excellence (NICE) before it could be routinely prescribed on the NHS. However, an EU green light would be a significant first step, potentially opening the door for early access schemes or compassionate use programmes in the meantime.
The broader biotech sector has been watching Scholar Rock closely, as apitegromab represents a novel approach to treating SMA by targeting muscle growth rather than solely addressing the underlying genetic defect. If approved, it could become a complementary therapy alongside existing gene therapies and splicing modulators. The FTSE 100 has been relatively steady today, with the index trading at 8,215 points, down 0.1 per cent, as investors weigh global economic data. However, biotech-focused funds and UK-listed pharmaceutical stocks have seen modest gains on the back of sector-wide optimism about upcoming drug approvals.
Industry commentators have pointed out that the UK's post-Brexit regulatory environment means the Medicines and Healthcare products Regulatory Agency (MHRA) can now diverge from EMA decisions, though it often follows suit. Should the EMA approve apitegromab, the MHRA could conduct its own review, potentially accelerating or delaying access for British patients. For now, the focus remains on the FDA's verdict, which is expected within days.